Article

Chemotherapy for recurrent cervical cancer.

Division of Gynecological Oncology, Department of Obstetrics and Gynecology, University Hospitals Leuven, Gasthuisberg, B-3000 Leuven, Katholieke Universiteit Leuven, Belgium.
Gynecologic Oncology (impact factor: 3.89). 11/2007; 107(1 Suppl 1):S113-8. DOI:10.1016/j.ygyno.2007.07.004 pp.S113-8
Source: PubMed

ABSTRACT To give an overview of chemotherapy schemes used in recurrent cervical cancer.
A pubmed search was performed using chemotherapy and recurrent cervical cancer including articles until April 2007.
Most recent articles and articles of interest are discussed.
Single agent cisplatin (50 mg/m2) remains the current standard for recurrent cervical cancer. Numerous chemotherapeutic agents have been tested but did not show convincing evidence of improved survival rates, except for the GOG 179 study which showed an improved survival for the combination of cisplatin and topotecan compared with single agent cisplatin. However, nearly 60% of patients in both groups received prior cisplatinum therapy as a radiosensitizer, which could be responsible for the development of platinum resistance, causing lower response and survival rates in the single platinum group. Hence, the apparent benefit in the doublet group is maybe just a reflection from the change in primary therapy and patient population. It is hoped that current trials comparing standard therapy with other single or doublet chemotherapeutic regimens or that the use of molecular-targeted agents will give us promising therapeutic options in the future.

0 0
 · 
0 Bookmarks
 · 
41 Views
  • Source
    Article: Surgical treatment of recurrent cervical cancer: state of the art and new achievements.
    Luis M Chiva, Fernando Lapuente, Lucía González-Cortijo, Antonio González-Martín, Alejandro Rojo, Juan F García, Natalia Carballo
    [show abstract] [hide abstract]
    ABSTRACT: This article review the current situation of the exenterative procedures as part of the treatment of recurrent cervical cancer after radiation. Pelvic exenteration has been proven the only curative choice of treatment in selected cases of this clinical situation. A review of historical and recent published series have shown an increase of 5-y survival from 30 to 42 %. Almost one out of two patients will suffer complications of some kind, and one out of three will have a severe complication with pelvic exenteration. During the past sixty years, a number of outstanding improvements have been achieved - not only in surgical outcomes, but also in quality of life - owing to new reconstructive approaches. Women facing an exenterative procedure must be counseled carefully about the risks and long-term concerns related to the procedure. Each should undergo a comprehensive evaluation to make sure there is no evidence of unresectable or metastatic disease that would make her an unsuitable candidate for exenteration.
    Gynecologic Oncology 09/2008; 110(3 Suppl 2):S60-6. · 3.89 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

apparent benefit
 
current standard
 
doublet chemotherapeutic regimens
 
doublet group
 
lower response
 
molecular-targeted agents
 
Numerous chemotherapeutic agents
 
overview
 
patients
 
platinum resistance
 
primary therapy
 
prior cisplatinum therapy
 
promising therapeutic options
 
pubmed search
 
recurrent cervical cancer
 
single platinum group
 
standard therapy
 
survival rates